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Mitochondria have long been implicated in the path-
ogenesis of Parkinson’s disease (PD). Mutations in
the mitochondrial kinase PINK1 that reduce kinase
activity are associated with mitochondrial defects
and result in an autosomal-recessive form of early-
onset PD. Therapeutic approaches for enhancing
the activity of PINK1 have not been considered
because no allosteric regulatory sites for PINK1 are
known. Here, we show that an alternative strategy,
a neo-substrate approach involving the ATP analog
kinetin triphosphate (KTP), can be used to increase
the activity of both PD-related mutant PINK1G309D
and PINK1WT. Moreover, we show that application
of the KTP precursor kinetin to cells results in biolog-
ically significant increases in PINK1 activity, manifest
as higher levels of Parkin recruitment to depolarized
mitochondria, reduced mitochondrial motility in
axons, and lower levels of apoptosis. Discovery of
neo-substrates for kinases could provide a hereto-
fore-unappreciated modality for regulating kinase
activity.INTRODUCTION
Parkinson’s disease (PD) is characterized by the loss of
dopaminergic (DA) neurons in the substantia nigra, a region
in the midbrain that is critical for motor control (Lang and
Lozano, 1998). Mitochondrial dysfunction has been closely
linked to PD via several mechanisms (Nunnari and Suoma-
lainen, 2012; Rugarli and Langer, 2012), including mutations
in the mitochondria-specific kinase PTEN-induced kinase 1
(PINK1) (Valente et al., 2004) and the mitochondria-associatedE3 ubiquitin ligase Parkin (Kitada et al., 1998). PINK1 plays an
important role in repairing mitochondrial dysfunction by
responding to damage at the level of individual mitochondria.
In healthy mitochondria, PINK1 is rapidly degraded by the pro-
tease ParL (Meissner et al., 2011), but in the presence of inner
membrane depolarization, PINK1 is stabilized on the outer
membrane, where it recruits and activates Parkin (Narendra
et al., 2010), blocks mitochondrial fusion and trafficking (Clark
et al., 2006; Deng et al., 2008; Wang et al., 2011), and
ultimately triggers mitochondrial autophagy (Geisler et al.,
2010; Narendra et al., 2008; Youle and Narendra, 2011). The
PINK1 pathway has also been linked to the induction of mito-
chondrial biogenesis and the reduction of mitochondria-
induced apoptosis in neurons, the latter phenotype due at
least in part to the effect of PINK1 on mitochondrial motility,
a neuron-specific phenotype (Deng et al., 2005; Petit et al.,
2005; Pridgeon et al., 2007; Shin et al., 2011; Wang et al.,
2011).
Individuals homozygous for PINK1 loss-of-function mutations
can develop a form of early-onset PD that results from highly
selective DA neuronal loss and that, in at least one clinical
case, shares the Lewy body pathology of sporadic PD (Gautier
et al., 2008; Geisler et al., 2010; Haque et al., 2008; Henchcliffe
and Beal, 2008; Petit et al., 2005; Samaranch et al., 2010).
Recent work has shown that, of 17 clinically relevant PINK1
mutations, those mutants that affect catalytic activity but do
not affect cleavage or subcellular localization have the most
dramatic effect on neuron viability, further supporting a role for
PINK1 activity in the prevention of neurodegeneration (Song
et al., 2013). One of the most common of the catalytic mutants,
PINK1G309D, shows an 70% decrease in kinase activity and
abrogates the neuroprotective effect of PINK1 (Petit et al.,
2005; Pridgeon et al., 2007). However, lower PINKG309D catalytic
activity can be rescued by overexpression of PINK1WT, and
increasing PINK1 activity by PINK1WT overexpression has been
shown to reduce staurosporine- and oxidative-stress-induced
apoptosis in multiple cell lines, suggesting that enhancedCell 154, 737–747, August 15, 2013 ª2013 Elsevier Inc. 737
PINK1 activity could be an effective therapeutic strategy for PD
(Arena et al., 2013; Deng et al., 2005; Kondapalli et al., 2012; Petit
et al., 2005; Pridgeon et al., 2007).
Recognizing the therapeutic potential of PINK1/Parkin path-
way activation, we began investigating mechanisms for the
pharmacological activation of PINK1. Small-molecule activation
of kinases is typically accomplished by binding allosteric regula-
tory sites. For example, natural products such as phorbol esters
bind to the lipid-binding domain of PKCs and recruit the kinase to
the membrane (Castagna et al., 1982; Nishizuka, 1984); sepa-
rately, the AMP-activated protein kinase (AMPK) is activated
by binding of AMP to an allosteric site (Ferrer et al., 1985; Hardie
et al., 2012). However, PINK1 contains no known small-molecule
binding sites. Another potential strategy might involve manipula-
tion of protein interaction sites or the active site, given that
synthetic ligands have been identified that bind to the protein
docking sites on the kinase PDK1 (Hindie et al., 2009; Wei
et al., 2010) and, separately, that Src activity can be controlled
by chemical complementation of an active site catalytic residue,
allowing ATP to be accepted only when imidazole was provided
to mutant Src (Ferrando et al., 2012; Qiao et al., 2006). However,
these approaches were not applicable to PINK1 as no structural
data for PINK1 are available.
We next turned our attention to sites within PINK1 known to
alter its function or stability. Four PINK1 disease-associated
mutations, including G309D, occur in an unusual insertion in
the canonical kinase fold. Human PINK1, as well as several or-
thologs, share three such large (>15 amino acid [AA]) insertions
in the N-terminal kinase domain (Figure S1A available online)
(Cardona et al., 2011; Mills et al., 2008) that provide the majority
of contacts to the adenine ring of ATP. Inserts in the active site of
several enzymes have been shown to alter substrate specificity.
In one example, the deubiquitinase UCH-L5 can hydrolyze larger
ubiquitin chains only when a >14 AA loop is present in the active
site (Zhou et al., 2012). In another example, protein engineering
of alkyl guanine DNA alkyltransferase through insertion of a
loop into the active site allows for recognition of an enlarged
O6-modified guanine substrate not accepted by the enzyme
without the loop insertion (Heinis et al., 2006). In light of these
findings, the three insertions in PINK1’s adenine-binding N-ter-
minal subdomain led us to believe that PINK1 might also exhibit
altered substrate specificity.
In considering the possibility that nucleotides other than ATP
could be substrates for kinases, we noticed that CK2 can utilize
multiple substrates as phospho-donors—guanosine triphos-
phate (GTP) as well as ATP, though its activity with GTP is
much lower (Niefind et al., 1999). Though it is uncommon for
eukaryotic protein kinases to accept alternative substrates in
the ATP binding site, kinases engineered with a single muta-
tion to the gatekeeper residue often tolerate ATP analogs with
substitutions at the N6 position (Liu et al., 1998b; Shah et al.,
1997). Importantly, no wild-type (WT) kinase we had previously
studied had shown the ability to accept N6-modified ATP ana-
logs (Figure S1B).
We discovered that, unlike any kinase we have studied, PINK1
accepts the neo-substrate N6 furfuryl ATP (kinetin triphosphate,
KTP) with higher catalytic efficiency than its endogenous sub-
strate, ATP. We also found that the metabolic precursor of this738 Cell 154, 737–747, August 15, 2013 ª2013 Elsevier Inc.neo-substrate (kinetin) can be taken up by cells and converted
to the nucleotide triphosphate form, which leads to accelerated
Parkin recruitment to depolarized mitochondria, diminished
mitochondrial motility in axons, and suppression of apoptosis
in human-derived neural cells, all in a PINK1-dependent manner.
RESULTS
PINK1 Accepts N6-Modified ATP Analog Kinetin
Triphosphate
We expressed both PINK1WT and PINK1G309D GST-tagged
kinase domains (156–496PINK1) in E. coli (Figure S2A) and per-
formed kinase assays with a series of neo-substrate analogs.
As expected, PINK1G309D displayed reduced activity with ATP;
interestingly, however, incubation with N6 furfuryl ATP (KTP) (Fig-
ure 1A) led to increased levels of transphosphorylation of the
mitochondrial chaperone hTRAP1 (residues 60–704) (Figure 1B)
and autophosphorylation with both PINK1G309D and PINK1WT
(Figures 1C and 1D). Using a phospho-peptide capture and
release strategy (Blethrow et al., 2008; Hertz et al., 2010), we
were able to identify the T257 autophosphorylation site
(Kondapalli et al., 2012) using KTP as the phospho-donor for
PINK1 (Figure 1E), which showed that this neo-substrate is
capable of supporting bona fide PINK1-dependent substrate
phosphorylation.
PINK1 is intrinsically highly unstable, especially so when pro-
duced in bacteria (Beilina et al., 2005); therefore, in order to
confirm the PINK1 dependency of the observed kinase activity,
we took several steps to optimize PINK1 expression. We con-
structed several FLAG3-tagged truncation variants of PINK1
and induced expression using baculovirus-infected SF21 insect
cells (Figure S2B). C-terminally tagged 112–581PINK1FLAG3 ex-
pressed the most soluble protein. However, the amount was
far below what we required for biochemical characterization
(Figure S2C). Hypothesizing that PINK1 might require interaction
with other proteins to fold properly, we coexpressed proteins
known to associate with PINK1, such as DJ-1, Parkin, and
TRAP1. Coexpression of full-length TRAP1 dramatically in-
creased the stability of PINK1 (Figure S2C). This finding enabled
us to express larger amounts of properly folded PINK1WT,
PINK1G309D, and a kinase-dead PINK1kddd (residues 112–581
with K219A, D362A, and D384A [Figure S1A]). In line with our
initial observations, SF21-produced-PINK1 activity is also
enhanced using KTP, but not other nucleotides (Figure 1F). We
confirmed that PINK1kddd has severely compromised activity
(Figures 1G and S2D) and were able to show that PINK1WT could
autophosphorylate with a 3.9 ± 1.3-fold higher (p = 0.02; t test)
Vmax and a higher KM (27.9 ± 4.9 mM versus 74.6 ± 13.2 mM) for
the neo-substrate KTP versus ATP (Figures 1G, S2E, and S2F).
As the previous assays utilized ATP with a g-thiophosphate as
a tracer, we wanted to confirm the activity using an orthogonal
tracer, g-32P ATP, to visualize PINK1 activity. Therefore, we
generated KTP with a g-32P-labeled phosphate and were able
to see that, using this orthogonally labeled version of KTP,
PINK1WT transphosphorylation of 60–704TRAP1 is increased rela-
tive to g-32P ATP (Figure S2G).
Because KTP would have to compete with millimolar
intracellular ATP concentrations in order to function, we
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Figure 1. Neo-Substrate KTP Amplifies PINK1 Kinase Activity In Vitro
(A) Chemical structure of kinase substrate adenosine triphosphate with gamma thiophosphate (ATPgS) and neo-substrate kinetin triphosphate gamma thio-
phosphate (KTPgS).
(B) PINK1 transphosphorylation kinase assay with 43 nM PINK1 and substrate 60–704TRAP1 (1 mg/ml highest concentration with 1:3 dilution across lanes) and
500 mM indicated nucleotide shown in (C); PINK1 activity was analyzed by immunoblotting for thiophospho-labeled TRAP1.
(D) PINK1 autophosphorylation kinase assay with 4.3 mM PINK1 and 100, 200, and 400 mM nucleotide (as indicated in C); PINK1 activity analyzed by immu-
noblotting for thiophospho-labeled PINK1.
(E) PINK1 autophosphorylation site identified by specific peptide capture and LCMSMS found only with PINK1WT and KTPgS, indicating that this nucleotide is
utilized as a bona fide substrate.
(F) SF21-produced PINK1 was incubated with 60–704TRAP1 and the indicated nucleotide (structure shown in C and analyzed as in B–D).
(G) PINK1 kinase assay with indicated nucleotide (250–1,250 mM in increments of 250 mM) analyzed as in (B–D) reveals much reduced phosphorylation activity
with PINK1KDDD (lanes 11–20); increased autophosphorylation was seen with neo-substrate KTPgS over endogenous substrate ATPgS.
See also Figures S1 and S2.performed a competition assay with g-thiophosphate-labeled
KTP versus ATP. We found that the KTPgS signal persisted
even when ATP was present at 4-fold greater concentrationthan KTPgS (2 mM versus 0.5 mM) (Figure S2H), suggest-
ing that PINK1 can be activated by KTP in the presence of
cellular ATP.Cell 154, 737–747, August 15, 2013 ª2013 Elsevier Inc. 739
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Figure 2. Neo-Substrate Precursor Kinetin
Leads to KTP in Human Cells and Acti-
vates PINK1-Dependent Phosphorylation
of Bcl-xL
(A) Schematic of the ribosylation reaction of kinetin
to KMP via APRT and PRPP followed by cellular
conversion to KTP.
(B) LCMS analysis of production of either AMP
(adenine) or KMP (kinetin and 9MK) by LCMS
analysis reveals that kinetin can undergo APRT
mediated ribosylation to KMP, but N9 methyl-
kinetin cannot.
(C) LCMS analysis of kinetin reaction; major peak
represents KMP+H peak at 428.3 mass/charge
ratio (m/z).
(D) HPLC analysis of standards (ADP, GTP, ATP,
KDP, KTP, and BTP), cellular lysate of DMSO, or
kinetin-treated HeLa cells with 250 mM BTP*
addition reveals a peak present in kinetin-treated
cells at 31.39 min.
(E) Absorbance spectrum of peak at 31.39 min in
kinetin-treated cells compared to absorbance
spectrum of KTP in standard cells.
(F) Zoom of HPLC analysis of DMSO or kinetin-
treated cell lysate with BTP addition or kinetin cell
lysate with BTP addition and KTP addition reveals
an increase in the peak that coelutes with KTP
(186%), where BTP decreases to 76% of original
area, suggesting that the peak is KTP.
(G) Immunoblot analysis with the indicated
antibodies for phosphorylation on serine 62 of
Bcl-xL reveals an increase following kinetin
treatment.
(H) Quantitative analysis of data shown in (G) in
which a significant increase in the phosphory-
lation of Bcl-xL on serine 62 with pretreatment
with kinetin versus DMSO or adenine (p = 0.01
and p = 0.04; t test) in SH-control expressing
cells not in SH-PINK1 cells. p values shown are
the result of two-tailed Student’s t test; *p <
0.05 and **p % 0.01; all values shown are
mean ± SEM.
See also Table 1 and Figure S3.KTP Is Produced in Human Cells upon Treatment with
KTP Precursor Kinetin
Our results showing in vitro increases in PINK1 activity using KTP
led us to investigate the ability to achieve enhanced activity of
PINK1 in cells. One major challenge to activating PINK1 in cells
is that ATP analogs, like KTP, are not membrane permeable;
however, previous work has shown that certain cytokinins can
be taken up by human cells and converted to the nucleotide
triphosphate form (Ishii et al., 2003). Additionally, recent work
in cells expressing hypomorphic mutant CDK2 alleles showed
that the activity of CDK2 could be increased in cells by providing
nucleotide analog precursors that can be converted to the nucle-
otide triphosphate form and are able to fit into the hypomorphic
CDK2 active site (Merrick et al., 2011).
The first step in bioconversion is ribosylation of the cytokinin to
a 50-monophosphate form, which can be mediated by adenine740 Cell 154, 737–747, August 15, 2013 ª2013 Elsevier Inc.phospho-ribosyl transferase (APRT) (Kornberg et al., 1955;
Lieberman et al., 1955b) (Figure 2A). Following established pro-
tocols (Parkin et al., 1984), we incubated adenine, kinetin, or
negative control N9 methyl-kinetin (9MK) with 50-phosphoribosyl
pyrophosphate (PRPP) and APRT and assayed the reaction by
LCMS (Figure 2B). Adenine converted rapidly to AMP, achieving
near-complete conversion (84%) after 10 min of reaction time;
kinetin’s conversion to KMP (Figures 2B and 2C) was markedly
slower, requiring 150 min for half to be converted. The control
compound 9MK is not converted to KMP even after 16 hr of in-
cubation (Figure 2B), whereas kinetin was completely converted
to KMP in this time frame. This experiment demonstrated that the
ribosylation of kinetin is biosynthetically possible using the enzy-
matic route for AMP production.
Our next step was to ask whether KMP could be converted
to the nucleotide triphosphate form (KTP) required for it to
Table 1. Measured Concentration of Nucleotides in HeLa Cell
Lysates
Concentration
ATP 1,950 ± 421 mM
KTP 68 ± 13.3 mM
See also Figures 2 and S3.serve as a neo-substrate for PINK1. Work by many labs has
demonstrated that ribosyl nucleotide analogs can be phos-
phorylated to nucleotide triphosphate forms by endogenous
enzymes (Krishnan et al., 2002; Lieberman et al., 1955a; Ray
et al., 2004). To confirm the presence of intracellular KTP
following incubation with kinetin, we adapted an ion-pairing
HPLC analysis method on a reverse-phase C18 column (Fig-
ure 2D) according to established methods (Vela et al., 2007).
After treatment with kinetin or DMSO, cells were lysed and
analyzed for the presence of peaks eluting at the retention
time of KTP. An internal standard of BTP (denoted by an asterisk
in Figures 2D, 2F, S3A, and S3B) was added following lysis.
Analysis of the kinetin-treated cells revealed a peak that coe-
lutes (offset by a consistent amount [Figure S3A]) with synthetic
KTP, a result not seen in any of our controls (Figures 2D, S3A,
and S3B). The UV absorbance maximummeasured with a diode
array detector is the same as KTP (Figure 2E) (absorbance peak
at 268 nm) and is significantly different than that of either ATP or
GTP (Figure S3C), both of which have significantly different
retention times. In a separate HPLC analytical run, an aliquot
of authentic KTP (to 80 mM) was added to authenticate the
putative KTP peak (Figure 2F). The peak grew to 186% of its
original area, whereas the peak of the standard BTP decreased
to 76% of its original area, suggesting that these were the same
substance. From these data, we calculate that an ATP concen-
tration of 1,950 ± 421 mM and a KTP concentration of 68 ±
13 mM (three biological replicates, Table 1) are produced upon
incubation with kinetin.
Kinetin Increases Phosphorylation of PINK1 Substrate
Antiapoptotic Protein Bcl-xL
Bcl-xL is a member of the Bcl-2 protein family that plays a
key regulatory role in mitochondrial-induced apoptosis (Adams
and Cory, 1998; Gross et al., 1999). PINK1 phosphorylates
Bcl-xL at serine 62 in response to mitochondrial depolarization
blocking cleavage to a proapoptotic form (Arena et al., 2013).
We therefore measured PINK1-dependent phosphorylation of
Bcl-xL in human SH-SY5Y cells following carbonyl cyanide
m-chlorophenyl hydrazone (CCCP)-induced depolarization.
We analyzed DMSO, 50 mM adenine, or 50 mM kinetin-treated
SH-SY5Y cells at 12 hr after 50 mM CCCP addition (Figure 2G)
and observed a significant (p = 0.01 and p = 0.04; t test) (Figures
2G and 2H) increase in phospho-Bcl-xL (S62) only in kinetin-
treated cells compared to DMSO or adenine, where PINK1
expression has not been silenced by small hairpin RNA (shRNA).
These results confirm that CCCP-mediated depolarization will
induce PINK1-dependent phosphorylation on S62 and suggest
that kinetin stimulates this activity in a PINK1-dependent
manner.Kinetin Accelerates Parkin Recruitment to Depolarized
Mitochondria in a PINK1-Dependent Manner
Parkin recruitment to depolarized mitochondria is PINK1 depen-
dent (Narendra et al., 2010); therefore, we postulated that
enhancement of PINK1 activity might accelerate this process.
We treated cells with either kinetin or adenine (Figure 3A)
and measured Parkin localization following CCCP-mediated
mitochondria depolarization. HeLa cells, which have low levels
of endogenous PINK1 and PARKIN, were transfected with
PINK1WT or PINK1G309D, mCherryParkin, and mitochondrial-
targeted GFP (mitoGFP). After 48 hr of incubation with 25 mM
adenine, kinetin, or equivalent DMSO (Figure 3B), we imaged
every 5 min following CCCP-mediated depolarization of mito-
chondria (Figures 3C, 3D, and S4A–S4F) and calculated the
percentage of GFP-labeled mitochondria with mCherryParkin
associated (Figures 3E and 3F and Table 2).
In line with previous reports (Narendra et al., 2010), transfec-
tion of PINK1G309D slowed the 50% recruitment (R50) time of
mCherryParkin to depolarized mitochondria (23 ± 2 min versus
15 ± 1 min R50) (Figure 3E and Table 2). The addition of kinetin,
but not adenine, decreased the R50 for Parkin in PINK1
G309D
cells from 23 ± 2 min to 15 ± 2 min and also decreased the
R50 for PINK1
WT cells from 15 ± 1 min to 10 ± 2 min (Figures
3E and 3F and Table 2). Using an image analysis algorithm (Fig-
ures S4G and S4H) that quantified the time-dependent change
in colocalization, we found that PINK1WT-expressing cells
achieved a maximum change in colocalization of 0.112 with
DMSO or adenine and 0.13 with kinetin treatment (Figure S4I).
PINK1G309D-expressing cells treated with DMSO or adenine
achieved a change in colocalization of 0.076, but upon addition
of kinetin, they returned to near-PINK1WT levels (0.124) (Fig-
ure S4J). These results suggested significant rescue of
PINK1G309D activity using kinetin. Two-way ANOVA analysis re-
vealed that kinetin has an effect in both cases (WT, F = 24.10
and p < 0.0001; G309D, F = 54.14 and p < 0.0001). Additionally,
in line with in vitro results in which benzyl triphosphate (BTP) did
not activate PINK1 as robustly as KTP (Figure 1F), benzyl
adenine is in general less active than kinetin in cells, although
it also demonstrated some acceleration of Parkin recruitment
(data not shown). However, benzyl adenine has been shown
to be cytotoxic in other assays (Ishii et al., 2002); therefore,
despite PINK1 activation potential of benzyl adenine, we
decided to focus on KTP to use as a neo-substrate to amplify
PINK1 activity.
To test the PINK1 dependency of our findings, we assayed
PINK1 activity by using phospho-specific antibodies raised
against the PINK1-specific S65 phospho-site on Parkin
(Kondapalli et al., 2012). We observed a small but repro-
ducible increase in the phosphorylation level of Parkin fol-
lowing CCCP treatment in a PINK1-dependent manner (Figures
S5A and S5B). In a finding that supported our colocalization
results, we also found that the addition of neo-substrate kinetin
(p = 0.03; t test), but not adenine (p = 0.30; t test), to
PINK1G309D mutant-expressing cells increased the phosphory-
lation levels of Parkin (Figures S5C and S5D). The addition of
an adenosine kinase inhibitor (AKI) blocking the conversion
of kinetin to KTP prevented this effect (p = 0.31; t test)
(Figure S5D).Cell 154, 737–747, August 15, 2013 ª2013 Elsevier Inc. 741
     adenine kinetin
PINK1G309D                                 PINK1wt
CCCP 15 mins                               CCCP 10 mins 
mitoGFP         Parkin           Merge
 
 
 
a
de
ni
ne
   
   
  k
in
et
in
   
   
  D
M
SO
 
+drug or DMSO +CCCP
transfection
48 hrs 24 hrs
A
D
E
B
F
mitoGFP         Parkin           Merge
 
 
 
a
de
ni
ne
   
   
  k
in
et
in
   
   
  D
M
SO
 
100
50
0
10 20 30
Time (min)
0Pa
rk
in
 re
cr
ui
tm
en
t 
 
 
 
 
 
 
(%
 of
 ce
lls
)100
50
Time (min)P
ar
ki
n 
re
cr
ui
tm
en
t 
 
 
 
 
 
 
(%
 of
 ce
lls
)
PINK1G309D PINK1wt
N
NNH
N
NH2
N
NNH
N
HN O
0
10 20 300
C
PINK1G309D adenine
PINK1G309D DMSO
PINK1G309D  kinetin
PINK1wt adenine
PINK1wt DMSO
PINK1wt  kinetin
Figure 3. PINK1 Neo-Substrate Kinetin Ac-
celerates PINK1-Dependent Parkin Recruit-
ment in Cells
(A) Chemical structure of adenine or kinase neo-
substrate precursor kinetin.
(B) Schematic depicting HeLa cell drug treatment.
(C and D) HeLa cells treated with indicated drug
and cotransfected with mitoGFP, mCherryParkin,
and indicated PINK1 construct imaged at either 10
or 15 min after 5 mM CCCP addition.
(E and F) Kinetin-treated cells reached R50 signif-
icantly faster than with adenine or DMSO (all data
shown are mean ± SEM) by two-way ANOVA
analysis; kinetin has an effect in both cases when
compared to adenine (WT, F = 25.41 and p <
0.0001; G309D, F = 31.89 and p < 0.0001) and
DMSO (WT; F = 21.94 p < 0.0001, G309D; F =
12.79, p < 0.0011). There was no significant dif-
ference for DMSO adenine in either case (at least
150 cells/experiment; n = 3 experiments; all values
are mean ± SEM).
See also Table 2 and Figure S4.Kinetin Blocks Mitochondrial Motility in Axons in a
PINK1-Dependent Manner
Increasing PINK1 activity markedly decreases the mobility of
axonal mitochondria, and this is thought to be the first step
in the sequestration and removal of damaged mitochondria
(Wang et al., 2011). To determine whether PINK1 activation by
kinetin also decreases mitochondrial motility, we examined the
mobility of axonal mitochondria in rat hippocampal neurons
cotransfected with mitoGFP to identify mitochondria and N-ter-
minal mCherry-tagged synaptophysin to identify axons (Hua
et al., 2011; Nakamura et al., 2011). Cells were pretreated for
48 hr with 50 mM kinetin, adenine, 9-methyl-kinetin (9MK, shown
in Figure 4A), or equivalent DMSO, and mitochondrial motility
was imaged live. Kymographs were generated (Figures 4B–4E)
using standard techniques. Kinetin markedly inhibited the per-
centage of moving mitochondria when compared to DMSO
(p = 0.0005; t test) (Figures 4D and 4F). In contrast, kinetin analog
9-methyl-kinetin (9MK) (Figures 4A, 4E, and 4F), which cannot
be converted to a nucleotide triphosphate form, did not affect742 Cell 154, 737–747, August 15, 2013 ª2013 Elsevier Inc.mitochondrial motility when compared
to DMSO (p = 0.86;t test). Kinetin also
produced a small decrease in the velocity
of mitochondria that remain in motion
(p = 0.03; t test) (Figure 4G).
To confirm that kinetin decreases mito-
chondrial motility through effects on
PINK1, we also performed experiments
in hippocampal neurons derived from
WT (C57BL/6) and PINK1 KOmice (Xiong
et al., 2009) after treatment with DMSO,
kinetin, or 9MK. Consistent with the
results in rat neurons, kinetin also signifi-
cantly decreased mitochondrial motility
in control neurons (p < 0.0001; t test)
when compared with either 9MK or
DMSO (Figures 4H and S5E). However,kinetin had no effect on the motility of mitochondria in PINK1
KO neurons (Figure 4H) (p = 0.64; t test), and unlike rat-derived
neurons, kinetin had no effect on the velocity of mitochondria
that remain in motion (Figure 4I). These data suggest that kinetin
can block mitochondrial motility in a PINK1-dependent manner
and that the metabolism of kinetin to KTP is a necessary precur-
sor for that effect.
Kinetin Decreases Apoptosis Induced by Oxidative
Stress in Human-Derived Neuronal Cells in a
PINK1-Dependent Manner
Previous studies have shown that PINK1 expression can block
apoptosis in response to proteosomal stress induced by the pro-
teosome inhibitor MG132 (Klinkenberg et al., 2010; Wang et al.,
2007). Caspase 3/7 activity is an early marker for apoptosis.
Therefore, to assess the ability of kinetin to amplify PINK1 activity
to block apoptosis, we measured caspase 3/7 activity using a
luminescence-based caspase 3/7 peptide cleavage assay in
HeLa cells. We treated HeLa cells transfected with Parkin with
Table 2. Time Required for 50% Recruitment of mCherry Parkin
to Depolarized Mitochondria
DMSO Adenine Kinetin
PINK1WT 14 ± 1 min 15 ± 1 min 10 ± 2 min
PINK1G309D 20 ± 2 min 23 ± 2 min 15 ± 2 min
See also Figures 3 and S4.DMSO or 25 mM adenine or kinetin for 48 hr, followed by 1 mM
MG132 for 12 hr. We found that kinetin significantly (p = 0.005
and p = 0.004; t test) reduced caspase 3/7 cleavage versus
DMSO or adenine pretreatment and that knockdown of PINK1
abrogated this effect (Figures 5A and S6A).
We then tested whether kinetin would be tolerated by
cultured DA neurons. Previous work has shown KTP precursor
kinetin to be extremely well tolerated in both mouse models
and in human clinical testing (Axelrod et al., 2011; Shetty
et al., 2011). To confirm these results, we treated DA neurons
with 50 mM kinetin or adenine and measured cell density after
10 days. Kinetin and adenine have no effect on cell density, indi-
cating that neither promotes apoptosis of cultured DA neurons
(Figure S6B).
We next utilized patient-derived neuroblastoma SH-SY5Y
cells, which are also known to exhibit decreased apoptosis
upon overexpression of PINK1 (Deng et al., 2005; KlinkenbergA
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0et al., 2010). We performed a dose-response assay in which
SH-SY5Y cells were treated with increasing concentrations of
kinetin, adenine, or DMSO for 96 hr and 1 mM MG132 for 16 hr,
followed by analysis for caspase 3/7 cleavage activity. As in
HeLa cells, kinetin pretreatment significantly decreased caspase
3/7 cleavage in SH-SY5Y cells (Figure 5B). Two-way ANOVA
analysis revealed that kinetin has an effect when compared to
DMSO or adenine (Figure 5B) (DMSO, F = 34.95 and p <
0.0001; adenine, F = 38.37 and p < 0.0001) only in cells in which
we did not silence PINK1 expression via stable shRNA expres-
sion (DMSO, F = 3.552 and p = 0.084; adenine, F = 1.7 and p =
0.215) (Figures 5B, S6C, and S6D) despite a small visible effect,
probably due to incomplete knockdown of PINK1 (Figure S6C).
These experiments suggest that the kinetin-induced reduction
in caspase 3/7 cleavage activity is PINK1 dependent.
To assay later stages of apoptosis in SH-SY5Y cells, we
utilized an independent fluorescence-activated cell sorting
(FACS)-based method to measure cellular apoptosis. In addi-
tion to proteosomal stress, PINK1 overexpression is known to
block apoptosis induced by H2O2 treatment (Deng et al.,
2005; Gautier et al., 2008; Petit et al., 2005; Pridgeon et al.,
2007). SH-SY5Y cells were treated with 50 mM kinetin, adenine,
or DMSO for 96 hr, followed by 400 mM H2O2 treatment for
24 hr. Using a cytometry-based FACS assay utilizing annexin
V and propidium iodide staining, we determined the percentage
of apoptotic cells after treatment with DMSO, adenine, orDMSO
adenine
kinetin
9MK
DMSO
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9MK
K1 KO
ns
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9MK
INK1 KO
kinetin
9MK
ns
Figure 4. Kinetin Halts Axonal Mitochon-
drial Motility in a PINK1-Dependent Manner
(A) Chemical structure of negative control non-
metabolizable kinetin analog 9-methyl-kinetin.
(B–E) Kymograph for analysis of mitochondrial
movement in representative PINK1WT-expressing
rat-derived hippocampal axons transfected with
mitoGFP. Scale bar, 10 mm.
(F) The percentage of time each mitochondrion
was in motion was determined and averaged.
Kinetin significantly blocks mitochondrial motility,
whereas 9MK has no effect (DMSO-kinetin, p =
0.0005; DMSO-9MK, p = 0.86).
(G) Kinetin induces a small decrease in velocity
(DMSO-kinetin, p = 0.03; DMSO-9MK, p = 0.24).
(H) Kymograph for analysis of mitochondrial
movement in C57BL/6 shows a response to kinetin
(kinetin 9MK, p < 0.0001), whereas in PINK1-
knockout-derived hippocampal axons, kinetin has
no effect (kinetin 9MK, p = 0.64).
(I) Both kinetin and 9MK have no effect on
mitochondrial velocity of moving mitochondrion
(C57BL/6 kinetin-9MK, p = 0.64; PINK1 KO, p =
0.074) (all values are mean ± SEM, analysis was
two-tailed Student’s t test).
See also Figure S5.
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SH-SY5Y Figure 5. Kinetin Inhibits Oxidative Stress-
Induced Apoptosis in Human Cells in a
PINK1-Dependent Manner
(A) Caspase 3/7 cleavage activity assay following
pretreatment with DMSO, adenine, or kinetin for
48 hr followed by MG132 treatment for 12 hr
compared to no MG132-treated cells reveals
reduced caspase 3/7 activity (p = 0.005 and p =
0.004; t test) only in sh-control-expressing cells
and not in cells expressing shRNA against PINK1.
(B) Caspase 3/7 cleavage activity of SH-SY5Y cells
pretreated with indicated concentration of adenine
or kinetin for 96 hr followed by MG132 treatment
for 12 hr in all conditions. Two-way ANOVA anal-
ysis revealed that kinetin has an effect when
compared to DMSO or adenine (Figure 5B)
(DMSO, F = 34.95 and p < 0.0001; adenine, F =
38.37 and p < 0.0001) but has no statistically sig-
nificant effect (DMSO, F = 3.552 and p = 0.084;
adenine, F = 1.7 and p = 0.215) in cells expressing
an shRNA against PINK1.
(C) SH-SY5Y cells pretreated as above were
stained with FITC conjugated Annexin V and pro-
pidium iodide and were analyzed by FACS.
(D) Quantification of (C) shows that kinetin-
treated cells have significantly lower induction of
apoptosis (DMSO-kinetin, p = 0.0023), but adenine
had no effect (DMSO-adenine, p = 0.09).
(E) Indicated SH-SY5Y cell lines were treated as in
(A). Kinetin-treated cells had significantly lower
induction of apoptosis only when PINK1 was
present (normalized to DMSO control untreated
cells; sh-control DMSO-kinetin, p = 0.008; sh-
PINK1 DMSO-kinetin, p = 0.23; sh-control DMSO-
adenine, p = 0.48; sh-PINK1 DMSO-adenine,
p = 0.23; all values are mean ± SEM; analysis was
Wilcoxon t test).
See also Figure S6.kinetin (Figure 5C). We observed a significant decrease in the
total amount of apoptotic cells following kinetin treatment
(Figure 5D) (DMSO versus kinetin, p = 0.0023; Wilcoxon T
test) but no significant change with adenine (DMSO versus
adenine, p = 0.09; Wilcoxon T test). Additionally, we observed
a significant drop in apoptosis in shRNA control lentivirus-
infected cells (DMSO versus kinetin, p = 0.008; Wilcoxon T
test) but no kinetin effect with infection of a lentivirus expressing
PINK1-silencing shRNA (Figures 5E and S6C) (DMSO versus
kinetin, p = 0.23; Wilcoxon T test). These results demonstrate
a PINK1-dependent antiapoptotic effect and suggest that
kinetin can activate PINK1 to block oxidative stress-induced
apoptosis of human neural cells.
DISCUSSION
Our investigation of a neo-substrate approach to modulating
PINK1 activity has yielded three significant findings: (1) that the744 Cell 154, 737–747, August 15, 2013 ª2013 Elsevier Inc.ATP analog KTP can be used by both
PINK1WT and PINK1G309D; (2) that KTP
enhances both PINK1WT and PINK1G309D
activity in vitro and in cells and, in thecase of the latter version, returns it to near-WT catalytic effi-
ciency; and (3) that KTP precursor kinetin can be applied to neu-
rons to enhance PINK1 activity in several biologically relevant
paradigms.
The finding that kinetin (or its nucleotide triphosphate form,
KTP) can restore PINK1G309D catalytic activity to near-WT levels
in vitro and in cells, in light of the fact that mutations in PINK1
produce PD in humans, raises the possibility that kinetin may
be used to treat patients who have mutant PINK1. Further,
because kinetin has already been shown to be well tolerated
in human trials (for familial dysautonomia, an unrelated splicing
disorder) and because previous work in mice has shown that
kinetin can cross the blood-brain barrier and achieve pharmaco-
logically significant concentrations (Axelrod et al., 2011; Shetty
et al., 2011), these results have the potential for near-term clinical
relevance.
Although mutations in PINK1 are a rare cause of PD, the
development of an effective disease-modifying therapy for
any neurodegenerative disease would be a tremendous
advance and could provide important therapeutic insights into
disease-modifying strategies for other types of PD. In fact,
the finding that increasing PINK1 activity beyond endogenous
levels can protect against a variety of apoptotic stressors
(Klinkenberg et al., 2010; Petit et al., 2005; Pridgeon et al.,
2007) and that kinetin can also reproduce this protection by
enhancing endogenous PINK1 function raises the possibility
that enhancing PINK1 activity may also have therapeutic poten-
tial for idiopathic PD.
Current kinase-targeted drugs are striking for the single
modality of regulating kinase function—inhibition. However, a
wide range of kinase dysregulation in disease is caused by a
lack of kinase activity: desensitization of insulin receptor kinase
in diabetes (Kulkarni et al., 1999); inactivation of the death-asso-
ciated protein kinase (DAPK) in cancer (Kissil et al., 1997); inac-
tivation of the LKB1 tumor-suppressor kinase in cancer (Gao
et al., 2011); and decreased PINK1 activity in early-onset
Parkinson’s disease. Although many examples of inactive
kinases causing disease have been uncovered, there have
been no therapeutic approaches for enhancing kinase activity
using alternative substrates. Our insights into the potential for
manipulating kinase-dependent cellular processes via a specif-
ically targeted neo-substrate may presage the ability to treat
other diseases resulting from kinase misregulation with an inno-
vative class of neo-substrate kinase activators.
EXPERIMENTAL PROCEDURES
Detailed methods for dopamine neuron cultures, PINK1 shRNA lentivirus pro-
duction, and apoptosis assays can be found in the Extended Experimental
Procedures.
Western Blot Analysis
Western blot analysis was carried out as described (Ultanir et al., 2012) with the
indicated antibodies. See Extended Experimental Procedures for details.
Expression, Purification, and Enzymatic Characterization of PINK1
H. sapiens PINK1 kinase domain (PINK1, residues 156–496; all plasmids
obtained from Addgene) with an N-terminal GST tag was expressed using a
pGEX vector using standard techniques. H. sapiens PINK1 kinase domain
with C-terminal extension (PINK1, residues 112–581) with a C-terminal
FLAG3 tag was coexpressed with full-length H. sapiens TRAP1 in the baculo-
virus/Sf21 insect cell system. Following lysis, PINK1112–581 kinase was purified
using magnetic M2 FLAG affinity resin (Sigma), and the kinase reaction was
performed on beads after no more than 2 hr following lysis. The reaction
was performed using 50 mM Tris-HCl, 150 mM NaCl, 10 mM MgCl2, 3 mM
MnCl2, 0.5 mM DTT, and 1 mg/ml substrate if not otherwise indicated.
After reaction at room temperature with rotation, the kinase reaction was
quenched with 50 mM EDTA and reacted with 1.5 mM p-nitrobenzylmesylate
(PNBM) and identified by immunoblot with anti-thiophosphate ester antibody
(Epitomics) (Allen et al., 2007).
Identification of PINK1 Autophosphorylation Site by Liquid
Chromatography-Tandem Mass Spectrometry
Protocol was carried out as described (Ultanir et al., 2012). See Extended
Experimental Procedures for details.
Enzymatic Production of KMP In Vitro
Reactions with APRT and PRPP and adenine, kinetin, or 9MK were carried out
as described (Parkin et al., 1984). See Extended Experimental Procedures for
details.HPLC Analysis for KTP Production in Cells
HeLa cells were incubated with the indicated drug for 96 hr, and nucleotides
were extracted and analyzed as described (Ray et al., 2004; Vela et al.,
2007). See Extended Experimental Procedures for details.
Parkin Mitochondrial Translocation Assay
HeLa cells were grown in DMEM supplemented with 10% FBS. Log phase
cells were plated in 24 well plates with glass coverslips (Mattek) pretreated
with fibronectin. Cells were pretreated with 25 mM of the indicated
compound, followed by transfection with MitoGFP, mCherryParkin, and
full-length PINK1FLAG3 in a 1:4:2 ratio using Fugene 6 (Promega). Fields
of cells were selected by expression of MitoGFP (six fields/well, three
wells/condition) and imaged at 5 min intervals following depolarization
with 5 mM CCCP. Quantification was performed according to published pro-
tocols (Narendra et al., 2010) and by implementing a Matlab-based script
(see Data S1).
Mitochondrial Motility Assay
All experiments were carried out according to IACUC guidelines, and UCSF
IACUC approved all experiments before execution. Primary hippocampal
cultures were prepared from early postnatal (P0 to P1) rat or mouse
(C57BL6 or Pink1/) pups, cotransfected by electroporation (Amaxa)
with mitochondrial-targeted GFP (mitoGFP) to visualize mitochondria,
and mCherry fused to synaptophysin (mCherrySynaptophysin) to visualize
axons. Cells were pretreated for 48 hr with 50 mM kinetin, adenine,
9-methyl-kinetin, or equivalent DMSO at day 9 and imaged live in Tyrode’s
medium (in mM: 127 NaCl, 10 HEPES-NaOH (pH 7.4), 30 glucose, 2.5 KCl,
2 CaCl2, and 2 MgCl2) with a 603 water immersion objective on a Nikon
Ti-E inverted microscope. Images were captured every 2 s for a total of
200 s, and kymographs were generated from each live-imaging movie with
Metamorph software (version 7.7.3.0). Mitochondria were considered moving
if they traveled more than 0.67 mm during the 200 s imaging.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
figures, and one data file and can be found with this article online at http://
dx.doi.org/10.1016/j.cell.2013.07.030.
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